Overview

This trial is active, not recruiting.

Conditions gastrointestinal carcinoid tumor, islet cell tumor, lung cancer, metastatic cancer, neoplastic syndrome
Treatments questionnaire administration, quality-of-life assessment
Phase phase 4
Sponsor National Cancer Institute (NCI)
Start date October 2006
Trial size 408 participants
Trial identifier NCT00454376, BNHFT-P4NET, CDR0000537344, EORTC-QLQ-G.I.NET21, EU-207101, EU-20712

Summary

RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors.

PURPOSE: This phase IV clinical trial is studying how well a disease-specific questionnaire works in assessing the quality of life of patients with gastrointestinal-related neuroendocrine tumors.

United States No locations recruiting
Other Countries No locations recruiting

Primary Outcomes

Measure
Reliability, scaling, scale correlation, and clinical validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21)
time frame:

Secondary Outcomes

Measure
Response to change after various treatments
time frame:

Eligibility Criteria

Male or female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Histologically confirmed neuroendocrine tumor OR characteristic radiological findings of neuroendocrine tumor with raised hormone levels in plasma or urine meeting any of the following criteria: - Primary disease in gut with liver metastases (with or without hormone secretion) - Primary disease in lung with liver or abdominal metastases (with or without hormone secretion) - Primary disease in pancreas with or without metastases (with or without hormone secretion) PATIENT CHARACTERISTICS: - Any Karnofsky performance status allowed - Life expectancy ≥ 3 months - Able to understand the questionnaire language - Mentally fit to complete questionnaire - No psychological, familial, sociological, or geographical condition that would limit study compliance - No other concurrent malignancies except basal cell carcinoma of the skin PRIOR CONCURRENT THERAPY: - More than 2 months since prior somatostatin analogue or interferon therapy (somatostatin therapy stratum) - Concurrent somatostatin analogue and/or interferon therapy allowed if dose stable over the past month - More than 6 months since prior radionuclide therapy or systemic chemotherapy (radionuclide or systemic chemotherapy stratum) - More than 6 months since prior ablative therapies (ablative therapy stratum) - No concurrent participation in other quality of life studies

Additional Information

Official title Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients With G.I.-Related Neuroendocrine Tumours
Description OBJECTIVES: Primary - Test the scale structure, reliability, and validity of the gastrointestinal neuroendocrine tumor module (QLQ-G.I.NET21) in patients with gastrointestinal-related neuroendocrine tumors. Secondary - Determine the quality of life of patients using QLQ-C30 and the QLQ-G.I.NET21 before and after treatment. OUTLINE: This is a multicenter study. Patients are stratified according to treatment (somatostatin analogue therapy or interferon therapy vs radionuclide therapy or chemotherapy vs ablative therapies [embolization or radiofrequency ablation] or liver resection). Patients complete the EORTC C30 questionnaire, QLQ-G.I.NET21 module, and are evaluated for Karnofsky performance status at pretreatment, at 3 and 6 months after treatment, and then 2 weeks later. Patients also complete a clinical data and sociodemographic data form and debriefing questionnaire at pretreatment; a follow-up form at 3 months and 6 months after treatment; and a test-retest form 2 weeks later. PROJECTED ACCRUAL: A total of 408 patients will be accrued for this study.
Trial information was received from ClinicalTrials.gov and was last updated in October 2013.
Information provided to ClinicalTrials.gov by National Cancer Institute (NCI).